Weekly Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings on May 17, 2018

May 17, 2018 - By Clyde Turner

Theravance Biopharma, Inc. (NASDAQ:TBPH) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.31. That’s change of 0.01, from 2017Q3’s 1.32. 7 investors sold all, 22 reduced holdings as Theravance Biopharma, Inc. ratio dived. 26 increased stakes while 12 funds acquired stakes. Funds hold 35.06 million shares thus 1.11% less from 2017Q3’s 35.46 million shares.
Alps Advsrs stated it has 59,951 shs or 0.01% of all its holdings. Swiss Bancorporation has 71,342 shs for 0% of their capital. Susquehanna Grp Inc Limited Liability Partnership, a Pennsylvania-based fund reported 30,359 shs. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 2,679 shs. Rock Springs Mngmt Ltd Partnership has 652,600 shs. Pnc Services Group Inc holds 0% or 36 shs in its capital. Manufacturers Life Ins The has 30,964 shs. Jacobs Levy Equity Management accumulated 15,500 shs or 0.01% of the stock. 125,849 were reported by Tiaa Cref Invest Mngmt Ltd. Barclays Public Ltd Com has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 8,892 shs. Wells Fargo And Co Mn stated it has 135,414 shs. Ameritas Investment Prtn Incorporated invested in 3,865 shs or 0.01% of the stock. Ny State Common Retirement Fund invested in 0% or 46,300 shs. Old West Mngmt Ltd Llc invested in 113,862 shs. 88,692 are owned by Balyasny Asset Mgmt Ltd Co.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

In total 3 analysts cover Theravance Biopharma (NASDAQ:TBPH). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:TBPH) has 100% bullish analysts. 4 are the (NASDAQ:TBPH)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Tuesday, February 27 Cantor Fitzgerald maintained the shares of TBPH in report with “Buy” rating. On Tuesday, May 8 the firm has “Buy” rating given by Cantor Fitzgerald. On Thursday, February 8 the firm earned “Outperform” rating by Leerink Swann. On Thursday, March 29 the firm earned “Buy” rating by Piper Jaffray. Listed here are Theravance Biopharma, Inc. (NASDAQ:TBPH) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0000 Maintain
29/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $45.0000 Initiate
27/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0 Maintain
08/02/2018 Broker: Leerink Swann Rating: Outperform Old Target: $45 New Target: $48 Maintain

Ticker’s shares touched $24.35 during the last trading session after 1.30% change.Theravance Biopharma, Inc. has volume of 175,081 shares. Since May 17, 2017 TBPH has declined 26.76% and is downtrending. The stock underperformed the S&P500 by 38.31%.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics.The firm is valued at $1.34 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.Currently it has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

More recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were brought out by Seekingalpha.com, Streetinsider.com and Prnewswire.com. The first one has “Theravance Biopharma’s (TBPH) CEO Rick Winningham on Q1 2018 Results – Earnings Call Transcript” as a title and was brought out on May 09, 2018. The next is “Theravance Biopharma (TBPH) Announces Approval of Expanded Indication in US for Once-Daily Trelegy Ellipta for …” on April 25, 2018. And last was brought out on April 20, 2018, called “Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical …”.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.